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REVIEW
Abstract: Targeting type 4 phosphodiesterase (PDE4) for treatment of COPD has multilevel 
beneﬁ  ts to patients by reducing inﬂ  ammation, relieving bronchoconstriction, and improving 
pulmonary circulation. The isoenzyme-speciﬁ  c narrow spectrum PDE4 inhibitors such as 
cilomilast and roﬂ  umilast may have limited clinical efﬁ  cacy in managing severe and very 
severe COPD. Development of dual therapy by combining PDE4 inhibition with Ca
2+ channel 
antagonism may introduce an effective novel armory for physicians to manage patients with 
severe COPD. 
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Introduction
Targeting type 4 phosphodiesterase (PDE4) has been recognized as a promising 
approach to managing COPD by relieving the symptoms, slowing the progress of 
the disease, increasing exercise tolerance, reducing exacerbation rate, and improving 
quality of life (Giembycz 2001, 2005; Mehats et al 2003; Spina 2003, 2004; Lagente 
et al 2005; Lipworth 2005; Soto and Hanania 2005) The pressing need to develop 
drugs that control symptoms and reduce mortality (Pauwels et al 2001; GOLD 
2005) and the billion-dollar marketing potential for management of COPD have 
pushed the R&D of PDE4 inhibitors into the product development pipelines of major 
pharmaceutical companies in the recent years. The early clinical trial data for the 
second-generation PDE4 inhibitors cilomilast (Ariﬂ  o
®, GlaxoSmithKline, USA) 
and roﬂ  umilast (Daxas
®, Altana, Germany) all pointed to a successful introduction 
of a novel non-steroid anti-inﬂ  ammatory therapy to clinicians in combating severe 
COPD (Gamble et al 2003; Rabe et al 2005) Nevertheless, while the progression of 
developing cilomilast has idled at the approvable stage for more than two years, the 
announcement of the termination of the agreement to develop roﬂ  umilast between 
Altana and Pﬁ  zer has raised concerns about the therapeutic efﬁ  cacy of selectively 
inhibiting one or two isoenzymes in the PDE4 family for COPD management 
(Pharmiweb 2005).
In the early six-month “RECORD” Phase III trial, roﬂ  umilast (500 mg daily) 
clearly improved lung function (ie, increased FEV1 by +97 mL) and signiﬁ  cantly 
reduced exacerbations (acute worsening of symptoms) compared with placebo (Rabe 
et al 2005). However, in the follow-up one-year Phase III trials using exacerbations 
as one of the key endpoints, the results from the European COPD RATIO study that 
included 1513 patients with severe and very severe COPD have failed to repeat the 
previously claimed efﬁ  cacy. In addition, the new trial data conﬁ  rmed that the PDE4 
inhibitor roﬂ  umilast’s efﬁ  cacy was considerably lower than the approved therapies 
such as ﬂ  uticasone/salmeterol (a combination therapy of glucocorticosteroid and 
long-acting β2-agonist) and tiotropium bromide (long-acting anticholinergic). The 
unexpectedly low long-term efﬁ  cacy on exacerbation rate from roﬂ  umilast therapy 
made the R&D community re-examine the role of targeting PDE4 in COPD because 
one of the highest unmet needs in treating the disease is to reduce or eliminate 
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exacerbations (Pharmiweb 2005). In November of 2005, 
Altana announced the withdrawal of the European 
Marketing Authorization Application (MAA) for roﬂ  umilast 
and decided to wait for more clinical trial data for submission 
of a future MAA (Altana 2005a). This holdup no doubt sets 
back the R&D of the most promising PDE4 inhibitor in 
development for COPD. 
PDE4 inhibition and COPD
COPD is a complex disease with pathophysiological features 
including inﬂ  ammation (neutrophils, macrophages, CD8+ 
lymphocytes inﬁ  ltration, and inﬂ  ammatory mediator TNF-
α and IL-8 release), airway obstruction (smooth muscle 
contraction, elevated cholinergic tone), respiratory 
bronchiolar–alveolar–vasculature remodeling (loss of 
elastic recoil, alveolar destruction, and ﬁ  brosis), pulmonary 
hyperinﬂ  ation,
 gas-exchange abnormalities, and pulmonary 
hypertension. The progressive loss of lung function leads 
to reductions in patients’ quality of life and results in 
exacerbations, cor pulmonale, and death. It is believed 
that the chronic non-infectious inflammation underlies 
the pathogenesis and the steady progression of the disease 
(Pauwels 2001; GOLD 2005). The pathological changes 
in the patients with COPD are not fully reversible and it 
often takes many years for a patient at risk (cough, sputum 
production) to progress into suffering from mild airﬂ  ow 
limitation, to moderate, severe, and very severe COPD (with 
chronic respiratory failure). In the absence of a magical 
therapy that can stop the disease progression and reverse 
the abnormalities of pulmonary function, the management, 
including drug therapy, for COPD is long-term care. 
Inhibition of PDE4 has been established as an effective 
and reliable approach to increasing intracellular cAMP 
(Conti et al 2003) that underlines the signaling mechanisms 
for the treatment of COPD. In recent years, numerous in 
vitro, in vivo, and clinical trial studies demonstrated that 
PDE4 inhibitors (eg, rolipram, cilomilast, and roﬂ  umilast) 
relax airway smooth muscles to increase air ﬂ  ow (Holbrook 
et al 1996; Bundschuh et al 2001) and improve pulmonary 
circulation (Schermuly 2000; de Witt 2000), inhibit 
bronchiolar–alveolar–vasculature remodeling, and ﬁ  brosis 
(Kumar et al 2003), reduce neutrophils–macrophages/CD8+ 
T cells inﬁ  ltration and pro-inﬂ  ammatory mediator release 
(Kumar et al 2003; Proﬁ  ta et al 2003; Wollin et al 2005), 
improve patients’ exercise capacity and quality of life, and 
prevent the progressive loss of pulmonary function (Rabe 
et al 2005; Gamble et al 2005). With all these preferred 
outcomes, it seems that the PDE4 inhibitors in development 
(cilomilast and roﬂ  umilast) would be an ideal armory for 
the healthcare community to combat COPD. Why, then, 
has the long-term trial with roﬂ  umilast failed to produce the 
expected results? It could be due to a dose regimen (500 mg 
daily) that was effective for patients with moderate to severe 
COPD (Rabe et al 2005) but not adequate for those patients 
suffering from severe and very severe COPD (Altana 2005b) 
or the intrinsic low efﬁ  cacy of the narrow-spectrum PDE4 
inhibitors. 
Subtype speciﬁ  c PDE4 inhibition 
and COPD
Developing PDE4 inhibitor as a therapy for COPD is 
based on the fact that theophylline dilates airway smooth 
muscles and improves pulmonary function by inhibition of 
PDE activity (Barnes 2003; Spina 2004) The dose-limiting 
adverse reactions (nausea, emesis, cardiac arrhythmias) 
with the non-selective PDE inhibitor theophylline and the 
ﬁ  rst-generation PDE4 inhibitor rolipram (Huang et al 2001; 
Lagente et al 2005) directed the R&D of PDE inhibitors to 
discover the second-generation of PDE4 inhibitors cilomilast 
and roﬂ  umilast that have been successfully brought to the 
ﬁ  nal stage for administration approval (Spina 2003, 2004; 
Lipworth 2005)
Based on the fact that the emetogenic reaction to PDE4 
inhibition is due to reticence of the PDE4D isoenzyme 
(Lamontagne et al 2001; Robichaud et al 2002), several 
researchers in the ﬁ  eld proposed to develop isoform-speciﬁ  c 
PDE4 inhibitors that reduce or completely avoid disturbing 
PDE4D activity and therefore do not trigger the emetic 
responses in the nervous system (Giembycz 2002; Robichaud 
et al 2002; Card et al 2004). 
Structural studies have provided evidence that the folding 
of catalytic domains of
 PDE4 has a conformation involved 
in binding of selective inhibitors with a common scheme: 
(i) a hydrophobic sub-pocket sandwiching an inhibitor in the 
active site; (ii) hydrogen bond(s) to an invariant glutamine 
controlling the orientation inhibitor binding (therefore the 
afﬁ  nity or potency) (Lee et al 2002; Huai et al 2003; Card 
et al 2004) (Figure 1). The scaffold of individual PDE4 
isoenzyme and the structure of a given selective inhibitor 
govern isoenzyme-selective inhibition, depict the binding 
afﬁ  nity, and determine the therapeutic window and rank 
order of potency in clinical use for the treatment of COPD. 
Enhancement of isoenzyme selectivity is critical
 for reduc-
ing side-effects of the PDE4 inhibitors. The strength of the 
interaction (hydrogen bond) between the oxygen group(s) International Journal of COPD 2006:1(4) 375
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of an inhibitor and the amide nitrogen group of glutamine 
(Gln) 369 for PDE4D and Gln 443 for PDE4B plays a 
pivotal role in determination of the potency and isoenzyme 
selectivity of an inhibitor (Lee et al 2002; Huai et al 2003; 
Card et al 2004). In addition, selective PDE4 inhibitors 
such as cilomilast and roﬂ  umilast have additional functional 
groups that can utilize the remaining empty space of the 
pocket to yield extra binding energy (increasing potency) 
and result in greater isoenzyme selectivity (Lee et al 2002; 
Huai et al 2003; Card et al 2004) 
For example, while cilomilast’s additional functional 
groups interact with 10 almost identical residues that form 
the hydrophobic sub-pocket in PDE4D and PDE4B, the 
oxygen atoms of the cyclopentyloxy and methoxy groups 
of cilomilast form two hydrogen bonds with the Gln369 of 
PDE4D, whereas there is only one hydrogen bond being 
formed between the methoxy group of cilomilast and the 
Gln 443 of PDE4B (Card et al 2004; comparing http://
www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/
GetPage.pl?pdbcode=1xom&template=ligands.html&l=1.1 
with http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/
pdbsum/GetPage.pl?pdbcode=1xlx& template=ligands. 
html&l=1.1). This difference may partially explain the fact 
that cilomilast is approximately 10-fold more selective for 
PDE4D than for PDE4B, despite over 90% identity between 
the PDE4B and PDE4D catalytic domains. (Giembycz 2001; 
Odingo 2005) 
Roﬂ  umilast shows a better ﬁ  tting to the hydrophobic 
sub-pocket in the PDE4D catalytic site than cilomilast 
(Card et al 2004; comparing http://www.ebi.ac.uk/thornton-
srv/databases/cgi-bin/pdbsum/GetPage.pl ?pdbcode=1xom& 
template=ligands.html&l=1.1 with http://www.ebi.ac.uk/
thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl? 
pdbcode=1xoq&template=ligands.html&l=2.1), which 
depicts the experimental ﬁ  nding that roﬂ  umilast inhibits 
PDE4D 338-fold more potently than cilomilast (Table 1). 
As for PDE4B inhibition, roﬂ  umilast’s cyclopropylmethoxy 
and diﬂ  uoromethoxy oxygen groups form two hydrogen 
bonds with Gln 443 of PDE4B (Card et al 2004; comparing 
http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/
pdbsum/GetPage.pl?pdbcode=1xmu & template 
=ligands.html&l=1.1 with http://www.ebi.ac.uk/
thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl? 
pdbcode=1xlx&template=ligands.html&l=1.1), which may 
partially explain its 585-fold greater inhibition potency than 
cilomilast toward PDE4b (Table 1). The dichloropyridyl 
substitution of roflumilast also increases its potency 
compared with cilomilast in terms of PDE4B inhibition 
(Card et al 2004).
The rank order of potency for inhibition of PDE4 
activity and lipopolysaccharide-stimulated TNFa release, for 
relaxing bronchoconstriction in guinea pigs, and the daily 
doses for treatment of COPD by roﬂ  umilast, cilomilast, 
rolipram, and theophylline are summarized in Table 2. 
By improving the inhibition ratio on PDE4B/PDE4D, 
roflumilast indeed lowers the emetic profile without 
compromising its therapeutic efﬁ  cacy in comparison to 
cilomilast (Huang et al 2001; Spina 2003)
The PDE4B-speciﬁ  c single-molecule targeting can 
undoubtedly reduce or eliminate an inhibitor’s unwanted 
effects. However, this approach may compromise the 
efﬁ  cacy of a PDE4 inhibitor because airway and vascular 
smooth muscles express multiple PDE4D isoforms 
Figure 1 Structures of representative PDE4 inhibitors. Asterisks indicate the 
oxygens that form hydrogen-bonds with Gln 369 of PDE4D and arrows indicate 
the hydrogen-bond(s) with Gln 443 of PDE4B. 
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Table 1 IC50 value comparison between roﬂ  umilast and 
cilomilast for phosphodiesterase (PDE) 4B and PDE4D 
inhibition
  PDE4B2 inhibition  PDE4D5 inhibition
 (IC50, nM)  (IC50, nM)
Roﬂ  umilast  0.41  0.81
Cilomilast 240  61
Data from Plexxikon, Inc. (2005).International Journal of COPD 2006:1(4) 376
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(eg, D1, D2, and D5) and PDE4D plays a crucial role 
in bronchoconstriction and vascular smooth muscle 
contraction (Liu et al 2000; Baillie et al 2001; Mehats 
et al 2003). An agent without 4D inhibition may end up 
lacking sufficient therapeutic efficacy for controlling 
COPD (Spina 2004).
PDE4 inhibition and pulmonary 
circulation
The beneﬁ  cial effects on COPD via relaxing airway smooth 
muscles and anti-inﬂ  ammation mediated by PDE4 inhibition 
with cilomilast and roﬂ  umilast have been emphasized and 
reviewed extensively (Spina 2004; Lagente et al 2005; 
Lipworth 2005; Soto 2005). Improving pulmonary 
circulation has not been considered as an important 
therapeutic approach for managing patients with COPD. 
However, the facts are 1) during COPD exacerbations, 
pulmonary hypertension (PH) is increased, 2) the presence 
of PH is recognized as the single strongest indicator of 
prognosis in COPD patients among the numerous clinically 
used lung function parameters (Doi et al 2003; Alp et al 
2006), and 3) clinically, the higher the pulmonary arterial 
pressure, the shorter the life expectancy of COPD patients 
(Barbera et al 2003). Although inhaling nitric oxide 
vasodilator can worsen gas exchange because of altered 
hypoxic regulation
 of ventilation-balance (Barbera 1996) in 
patients with stable COPD, and vasodilators are considered 
as contraindications for COPD patients, in their preliminary 
clinical trial, Alp et al (2006) demonstrated that reduction 
of pulmonary vasculature resistance using the PDE5 
inhibitor sildenaﬁ  l was able to signiﬁ  cantly improve the 
exercise capacity (6-minute walk test) of patients suffering 
from severe COPD. A double-blinded, placebo-controlled, 
crossover clinical trial of sildenaﬁ  l in patients (n=10) with 
COPD is going on to evaluate the effect of PDE5 inhibition 
on patients’ exercise function, pulmonary function, and 
quality of life (National Institutes of Health). 
Although there is a lack of reports about cilomilast- or 
roﬂ  umilast-caused PDE4 inhibition on the improvement 
of pulmonary circulation, in isolated perfused lung 
preparations, intravascular or transbronchial administration 
of subthreshold doses of the wide-spectrum PDE4 
inhibitor rolipram synergistically ampliﬁ  ed the pulmonary 
vasodilatory response to inhaled PGI2 and concomitantly 
improved ventilation–perfusion matching and relieved 
pulmonary hypertension (Schermuly et al 2000). More 
interestingly, in anesthetized cats, De Witt et al (2000) 
found that rolipram was more potent than either siguazodan 
(PDE3 inhibitor) or zaprinast (PDE5 inhibitor) in reducing 
pulmonary lobar arterial pressure. When the tone in the 
pulmonary vascular bed was raised to a high steady 
level with a constant infusion of the thromboxane mimic 
U46619 (9,11-dideoxy-11, alpha9alpha-epoxymethano 
prostaglandin F2α), intralobar injections of rolipram caused 
dose-related decreases in systemic arterial pressure and 
pulmonary arterial pressure. The preference reduction in 
pulmonary arterial pressure by inhibition of PDE4 suggests 
that administration of PDE4 inhibitors may beneﬁ  t COPD 
patients by increasing ventilation (airway relaxation) and 
improving alveolar perfusion (vasodilation), therefore 
improving blood–gas exchange capacity and patients’ 
pulmonary function. 
Thus, it is highly likely that the maximal therapeutic 
efﬁ  cacy of targeting PDE4 in the treatment of severe 
COPD depends upon three effectors of downstream 
intracellular cAMP elevation: 1) anti-inflammation 
(Lipworth 2005), 2) airway relaxation (Spina 2004), and 
3) vasodilation. Sacriﬁ  cing any one of these effectors with 
an isoenzyme-speciﬁ  c narrow-spectrum PDE4 inhibitor 
will compromise the effectiveness of the therapy. How, 
then, is the dose-limiting dilemma (nausea, vomiting, 
diarrhea, and arteritis) (Giembycz 2005; Spina 2004; 
Lipworth 2005) associated with the wide-spectrum PDE4 
inhibition overcome? 
Table 2 Potency comparison between phosphodiesterase inhibitors
 PDE4  inhibition  TNF-α release  Bronchorelaxation  Dosage for COPD
 (IC50, nM)
a (IC50, nM)
a (EC50, μmol/kg)
b (mg,  daily)
c
Roﬂ  umilast  0.8  20  1.5  0.5
Cilomilast 120  1300  52.2  15  twice
Rolipram 1100 30  32.5  -
Theophylline >10 000 >10 000 >300  100–600
aLeadDiscovery; Yoshimura et al (1995); Tenor et al (1996).
bBundschuh et al (2001; Holbrook et al (1996).
cGOLD (2005); Gamble et al (2003); Rabe et al (2005); Lipworth (2005).International Journal of COPD 2006:1(4) 377
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Approaches for improving the 
therapeutic efﬁ  cacy of PDE4 
inhibitors 
The fact that there are over 60 PDE isoenzymes en-
coded by 21 human PDE genes and at least 16 PDE4 
isoenzymes from 4 PDE4 genes (Soderling and Beavo 
2000; Conti et al 2003; Houslay and Adams 2003; Huai 
et al 2004) may render it highly possible that searching for 
isoenzyme-speciﬁ  c PDE4 inhibitors will yield low-efﬁ  cacy 
agents. In addition, mechanisms for upregulation of PDE4 
activity by cAMP-induced PDE4 gene expression and 
PKA-catalyzed phosphorylation–activation of PDE4 isoforms 
(Conti et al 2003; Wallace et al 2005) may very likely reverse 
an isoenzyme-speciﬁ  c, PDE4 inhibitor-produced elevation 
of intracellular cAMP level, and therefore the associated 
biological beneﬁ  cial effects. 
Noticing the low therapeutic ratio and insufficient 
clinical efﬁ  cacy of the current generation of PDE4 inhibitors 
(cilomilast and roﬂ  umilast), Giembycz (2005) assumed that 
one potential means of improving the therapeutic ratio and 
safety of PDE4 inhibitors may lie in the development of 
compounds that have broader phosphodiesterase speciﬁ  city 
and suggested dually targeting PDE4 and PDE1, PDE3, or 
PDE7 to enhance clinical efﬁ  cacy. This approach seems to 
revisit the previously well-described PDE inhibitors such 
as theophylline or zardvarine (Schmidt et al 2000; Barnes 
2003). It may lead to the dose-limiting drawback cycle again, 
because it is known that targeting cAMP-speciﬁ  c PDE3 is 
associated with an increase in morbidity and mortality in 
heart failure patients (Packer et al 1991). 
In a news feature on Pharmiweb.com, there is a remark 
about Pﬁ  zer’s development of an inhaled dual-action PDE4/
Spiriva
® (long-lasting muscarinic antagonist tiotropium) 
combination product for COPD (Pharmiweb 2005). This 
combined dual action modality is a favorable approach 
for managing patients with severe COPD considering 
the presence of bronchoconstricting and inflammatory 
pathologies in the disease. In general, moderately targeting 
two mechanisms to reach the therapeutic goal should be more 
effective and safer than exploiting a single mechanism to its 
extended degree. 
We have proposed to co-administer Ca
2+ channel 
antagonist (CCA) to overcome PDE4 inhibitor-caused 
adverse effects, especially emetic responses (Wang and 
Wang 2005) because 1) stimuli that upregulate the cAMP 
pathway can increase the excitability of the neurons in the 
locus coeruleus (LC) that plays an important role in 
mediating neuronal emesis (Nestler et al 1999; Takeda et al 
2001); 2) the PDE4D isoform is localized to neurons in the 
structures of the medulla including LC (Lamontagne et al 
2001), which are consistent with a role for PDE4D in the 
emetic response; and 3) the LC neurons ﬁ  re action potentials 
spontaneously, resulting from endogenous properties of 
the membrane conductance to a persistent inward Ca
2+ 
current, which can be blocked by diltiazem (Williams et al 
1984; Tokuyama and Ho 1996; Filosa and Putnam 2003). 
Thus, in the presence of CCA, even when a complete 
inhibition of PDE4D leads to an elevation of cAMP in the 
LC neurons, the LC cells will not be able to ﬁ  re action 
potentials due to a blockade of the depolarizing L-type Ca
2+ 
currents, therefore eliminating the intrinsic dose-limiting 
emetic pharmacological proﬁ  le of the wide-spectrum PDE4 
inhibition. In addition, CCAs also relax airway smooth 
muscles and exhibit anti-inﬂ  ammatory effects, which may 
synergistically augment a PDE4 inhibitor’s therapeutic 
effects on COPD (Worley and Kotlikoff 1990; Szabo et al 
1997; Brown et al 2004). The clinical use of CCAs in 
treatment of pulmonary hypertension in patients with COPD 
further support the combination therapy of a PDE4 inhibitor 
and a CCA (Sajkov et al 1997). One concern regarding the 
combined therapy is the possible difference between the 
pharmacokinetics of the two drugs that may compromise 
the expected outcomes. This pitfall can be eliminated by 
developing an agent with two pharmacophores in one 
chemical structure, therefore being able to simultaneously 
target two therapeutic mechanisms such as L-type Ca
2+ 
channels and PDE4s (Wang and Wang 2005). This design 
should greatly improve the tolerability of PDE4 inhibition 
in COPD patients. We believe that it is worthwhile to carry 
out a randomized clinical trial to evaluate the safety and 
efﬁ  cacy of dually targeting PDE4 and Ca
2+ channels in 
managing the patients with severe COPD. 
Conclusion
The unsatisﬁ  ed efﬁ  cacy of using PDE4 inhibitor roﬂ  umilast 
in treatment of severe and very severe COPD has raised 
concerns in the R&D community about the administrative 
approvability for the highly expected novel therapeutic 
modality in combating COPD. The extensive in vitro, in 
vivo, and clinical trial study data and the established clinical 
beneﬁ  cial effects (anti-inﬂ  ammation, bronchorelaxation, 
pulmonary vasodilation) associated with PDE4 inhibition 
strongly validate targeting PDE4 for controlling COPD. 
Development of an inhaled dual-action therapy such as International Journal of COPD 2006:1(4) 378
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PDE4 inhibitor and muscarinic antagonist may be a correct 
approach to bringing a PDE4 inhibitor to the demanding 
market. The other approach is using CCA to overcome 
PDE4 inhibitor-caused adverse effects, especially emetic 
responses and simultaneously enhance PDE4 inhibitor’s 
anti-inflammatory and bronchorelaxation, pulmonary 
vasodilation effects. Of course, development of a dual agent 
that has with two pharmacophores in one chemical structure, 
therefore being able to target PDE4 and L-type Ca
2+ channels 
should also be able to improve the therapeutic window of 
PDE4 inhibition and may make available a new therapeutic 
approach to managing COPD. 
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